A combination of Deferoxamine mesylate and minimally invasive surgery with hematoma lysis for evacuation of intracerebral hemorrhage. Issue 2 (February 2020)

• Record Type: Journal Article
• Authors: Pandey, Aditya S; Daou, Badih J; Chaudhary, Neeraj; Xi, Guohua
• Is Part Of: Journal of cerebral blood flow & metabolism. Volume 40:Issue 2(2020)
• Page Start: 456
• Page End: 458
• Publication Date: 2020-02
• Subjects: Deferoxamine -- intracerebral hemorrhage -- hematoma lysis -- intracerebral hematoma evacuation; Cerebral circulation -- Periodicals; Brain -- Metabolism -- Periodicals; Brain -- Blood-vessels -- Periodicals; Cerebrovascular disease -- Periodicals; 612.824
• DOI: 10.1177/0271678X19892660
• Languages: English
• ISSNs: 0271-678X

Abstract

Intracerebral hemorrhage is associated with significant morbidity and mortality. Some clinical trials demonstrated a trend towards benefit with surgical evacuation of intracerebral hemorrhage, without strong statistically significant results. Subsequent studies focused on minimally invasive techniques. Improved outcomes were more likely with surgical reduction of intracerebral hemorrhage volume to ≤15 mL. Deferoxamine is currently being evaluated as a therapeutic tool in intracerebral hemorrhage with promising results. There continues to be a lack of level I evidence supporting medical and surgical tools for intracerebral hemorrhage evacuation. Could a combination of minimally invasive surgery with hematoma lysis and Deferoxamine result in more effective hematoma evacuation?